930798-40-6

Upstream product

• 34743-88-9 2-(4-bromophenoxy)ethanol 
• 55162-34-0 1-bromo-4-(2-chloroethoxy)benzene 
• 106-41-2 4-bromo-phenol 
• 877995-77-2 1-(4-bromophenoxy)-2-(2,6-dichloro-4-methylphenoxy)ethane 

Downstream Products

• 946003-24-3 (3R,4S)-4-{4-[2-(2,6-Dichloro-4-methyl-phenoxy)-ethoxy]-phenyl}-piperidine-1,3-dicarboxylic acid 1-tert-butyl ester 
• 1026786-65-1 1-tert-butyl 3-ethyl (3R,4S)-4-{4-(2-(2,6-dichloro-4-methyl-phenoxy)ethoxy)phenyl}-piperidine-1,3-dicarboxylate 
• 1026787-16-5 tert-butyl (3R,4S)-3-{[[3-hydroxy-5-(3-methoxypropyl)benzyl](cyclopropyl)amino]carbonyl}-4-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]phenyl}piperidine-1-carboxylate 
• 1026787-15-4 tert-butyl (3R,4S)-3-({[3-{[(tert-butyl)(dimethyl)silyl]oxy}-5-(3-methoxypropyl)benzyl](cyclopropyl)amino}carbonyl)-4-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]phenyl}piperidine-1-carboxylate 
• 1026787-28-9 tert-butyl (3R,4S)-3-(((3-((1-(cyanomethyl)cyclopropyl)methoxy)-5-(3-methoxypropyl)-benzyl)(cyclopropyl)amino)carbonyl)-4-(4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)phenyl)-piperidine-1-carboxylate 
• 1026787-31-4 tert-butyl (3R,4S)-3-({[(cyclopropyl)(1R,2R)-3-{[2-(ethoxycarbonyl)cyclopropyl]methoxy}-5-(3-methoxypropyl)benzyl]amino}carbonyl)-4-(4-{2-[(2,6-dichloro-4-methylphenoxy)ethoxy]phenyl})piperidine-1-carboxylate 
• 1087347-05-4 ethyl (1R,2R)-2-{[3-({(cyclopropyl)[((3R,4S)-4-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]phenyl}piperidin-3-yl)carbonyl]amino}methyl)-5-(3-methoxypropyl)phenoxy]methyl}cyclopropane-1-carboxylate 
• 1087347-39-4 tert-butyl (3R,4S)-3-{[[3-(3-cyanopropoxy)-5-(3-methoxypropyl)benzyl](cyclopropyl)amino]carbonyl}-4-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]phenyl}piperidine-1-carboxylate 
• 1087347-44-1 tert-butyl (3R,4S)-3-({(cyclopropyl)[3-(4-methoxy-3,3-dimethyl-4-oxobutoxy)-5-(3-methoxypropyl)benzyl]amino}carbonyl)-4-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]phenyl}piperidine-1-carboxylate 
• 1087347-30-5 (1R,2R)-2-{[3-{[[((3R,4S)-1-(tert-butoxycarbonyl)-4-{4-[2-(2.6-dichloro-4-methylphenoxy)ethoxy]phenyl}piperidin-3-yl)carbonyl](cyclopropyl)amino]methyl}-5-(3-methoxypropyl)phenoxy]methyl}cyclopropane-1-carboxylic acid 
• 1087347-42-9 tert-butyl (3R,4S)-3-{[[3-[(4-cyanobenzyl)oxy]-5-(3-methoxypropyl)benzyl](cyclopropyl)amino]carbonyl}-4-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]phenyl}piperidine-1-carboxylate 
• 1087347-40-7 tert-butyl (3R,4S)-3-[((cyclopropyl){3-(3-methoxypropyl)-5-[3-(2H-tetrazol-5-yl)propoxy]benzyl}amino)carbonyl]-4-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]phenyl}piperidine-1-carboxylate 
• 1087347-38-3 tert-butyl (3R,4S)-3-({(cyclopropyl)[3-(4-ethoxy-4-oxobutoxy)-5-(3-methoxypropyl)benzyl]amino}carbonyl)-4-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]phenyl}piperidine-1-carboxylate 
• 1087347-34-9 tert-butyl (3R,4S)-3-({(cyclopropyl)[3-{[1-(2-methoxy-2-oxoethyl)cyclopropyl]methoxy}-5-(3-methoxypropyl)benzyl]amino}carbonyl)-4-{4-[2-(2.,6-dichloro-4-methylphenoxy)ethoxy]phenyl}piperidine-1-carboxylate 

Relevant academic research and scientific papers

NOVEL CASE OF RENIN INHIBITORS

The present invention relates to piperidine-based renin inhibitor compounds having carboxylate or carboxylic acid terminal groups. The disclosed low molecular weight, orally active renin inhibitors are of non-peptide nature and have long duration of action. The compounds can be used in the treatment of cardiovascular events and renal insufficiency.

RENIN INHIBITORS

The present invention relates to disubstituted piperidinyl renin inhibitor compounds having the structure (Formula I) and their use in treating cardiovascular events and renal insufficiency.

A PROCESS FOR PREPARING DIAZABICYCLO[3.3.1] NONANE COMPOUNDS

The invention is a process for preparing a diazabicyclo compound of formula (I) process for preparing a diazabicyclo compound of formula (I):where X is selected from the group consisting of hydrogen, C1-C6 alkoxycarbonyl, and carbobenzyloxy; R6 is selected from the group consisting of C1-C6 alkyl, C2-C6 alkenyl, and benzyl; and R9, R 10, and R11 are independently selected from the group consisting of hydrogen, halogen, and C1-C6 alkyl. wherein the process involves cyclizing I-I, formula (II).

PYRROLIDINE-3-CARBOXYLIC ACID AMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF RENIN

The invention relates to novel pyrrolidine-3-carboxylic acid amide derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of these novel compounds, pharmaceutical compositions comprising such compounds and especially the use of such compounds as inhibitors of renin.